Ann F Cheung

This inventor holds 13 USPTO granted patents and 49 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignee: Dragonfly Therapeutics, Inc.. Active years: 2023-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ann F Cheung. Retrieved from https://idiyas.com/inventor/ann-f-cheung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 49)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 42)

EPO Patents = 5 (Patent Applications = 47)

Average Co-Inventor Count = 6.7

ph-index = 4

Forward Citations = 34(Granted Patents)

Company Filing History:

13 out of 14

Dragonfly Therapeutics, Inc.

patents

Years Active: 2023-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12384851 - Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use (2025-08-12),

2. 12384847 - Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen (2025-08-12),

3. 12378318 - Proteins binding NKG2D, CD16 and a tumor-associated antigen (2025-08-05),

4. 12275791 - Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use (2025-04-14),

5. 12264200 - Antibody variable domains targeting the NKG2D receptor (2025-04-01),

6. 12215157 - Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use (2025-02-04),

7. 12157771 - Proteins binding NKG2D, CD16 and CLEC12A (2024-12-03),

8. 12129300 - Antibody variable domains targeting the NKG2D receptor (2024-10-29),

9. 11939384 - Antibody variable domains targeting the NKG2D receptor (2024-03-26),

10. 11884733 - Antibody variable domains targeting the NKG2D receptor (2024-01-30),

11. 11884732 - Proteins binding HER2, NKG2D and CD16 (2024-01-30),

12. 11834506 - Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer (2023-12-05),

13. 11787864 - Heterodimeric Fc-fused proteins (2023-10-17),

Title: Innovations in Cancer Therapy by Ann F Cheung

Introduction

Ann F Cheung is a prominent inventor based in Lincoln, MA (US), known for her significant contributions to cancer therapy. With a total of 13 patents to her name, she has been at the forefront of developing innovative treatments that target cancer cells effectively.

Latest Patents

Her latest patents include multi-specific binding proteins that bind to B-cell maturation antigen (BCMA), NKG2D, and CD16. These proteins are designed to kill human cancer cells and are accompanied by pharmaceutical compositions and therapeutic methods useful for cancer treatment. The multi-specific binding proteins exhibit high potency and maximum lysis of target cells compared to traditional anti-BCMA monoclonal antibodies. Additionally, she has developed cancer therapy involving an anti-PD1 antibody in combination with a multi-specific binding protein that binds to a tumor-associated antigen, NKG2D receptor, and CD16. This combination therapy aims to enhance the effectiveness of cancer treatment.

Career Highlights

Ann F Cheung is currently associated with Dragonfly Therapeutics, Inc., where she continues to innovate in the field of cancer research. Her work has been instrumental in advancing therapeutic methods that improve patient outcomes.

Collaborations

Some of her notable coworkers include Asya Grinberg and William Haney, who contribute to the collaborative efforts in developing groundbreaking cancer therapies.

Conclusion

Ann F Cheung's innovative work in cancer therapy exemplifies the potential of multi-specific binding proteins in treating complex diseases. Her contributions are paving the way for more effective cancer treatments and improving the lives of patients.

Profile summary based on public USPTO records.